|
TW201629069A
(zh)
*
|
2015-01-09 |
2016-08-16 |
霍普驅動生物科技股份有限公司 |
參與協同結合之化合物及其用途
|
|
KR102598895B1
(ko)
|
2016-07-12 |
2023-11-07 |
레볼루션 메디슨즈, 인크. |
다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
|
|
MX2019008695A
(es)
|
2017-01-23 |
2019-09-11 |
Revolution Medicines Inc |
Compuestos biciclicos como inhibidores alostericos de shp2.
|
|
MX2019008696A
(es)
|
2017-01-23 |
2019-09-13 |
Revolution Medicines Inc |
Compuestos de piridina como inhibidores de shp2 alostericos.
|
|
MX2020003579A
(es)
|
2017-10-12 |
2020-07-22 |
Revolution Medicines Inc |
Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos.
|
|
BR112020009757A2
(pt)
|
2017-12-15 |
2020-11-03 |
Revolution Medicines, Inc. |
compostos policíclicos como inibidores alostéricos de shp2
|
|
KR20210116479A
(ko)
*
|
2018-12-21 |
2021-09-27 |
레볼루션 메디슨즈, 인크. |
공동 결합에 참여하는 화합물 및 그의 용도
|
|
WO2021091956A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN120699039A
(zh)
*
|
2019-11-04 |
2025-09-26 |
锐新医药公司 |
Ras抑制剂
|
|
MX2022005359A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
|
US20210322405A1
(en)
*
|
2020-04-15 |
2021-10-21 |
Washington University |
Compositions and methods for treating cancer
|
|
IL299131A
(en)
|
2020-06-18 |
2023-02-01 |
Revolution Medicines Inc |
Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
|
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
|
MX2023003060A
(es)
|
2020-09-15 |
2023-04-05 |
Revolution Medicines Inc |
Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
|
|
AU2021401741A1
(en)
*
|
2020-12-17 |
2023-06-29 |
Blossomhill Therapeutics, Inc. |
Macrocycles and their use
|
|
CN116635076A
(zh)
*
|
2020-12-17 |
2023-08-22 |
荣山医药股份有限公司 |
大环化合物及其用途
|
|
IL307396A
(en)
*
|
2021-04-02 |
2023-12-01 |
Massachusetts Gen Hospital |
Methods for inhibiting RAS
|
|
US20240217960A1
(en)
*
|
2021-04-09 |
2024-07-04 |
Universität Basel |
Triazine derivative as covalent inhibitors of pi3k
|
|
WO2022235866A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
|
AU2022268962A1
(en)
*
|
2021-05-05 |
2023-12-14 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
|
MX2023013912A
(es)
|
2021-05-25 |
2024-02-12 |
Revolution Medicines Inc |
Metodos para inhibir ras.
|
|
EP4346826A4
(en)
*
|
2021-05-27 |
2025-04-30 |
Mirati Therapeutics, Inc. |
COMBINATION THERAPIES
|
|
WO2023015559A1
(en)
*
|
2021-08-13 |
2023-02-16 |
Nutshell Biotech (Shanghai) Co., Ltd. |
Macrocycle compounds as inhibitors of ras
|
|
AR126854A1
(es)
|
2021-08-27 |
2023-11-22 |
Hoffmann La Roche |
Compuestos macrocíclicos para el tratamiento de cáncer
|
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
|
TW202400607A
(zh)
*
|
2022-04-25 |
2024-01-01 |
美商翰森生物有限責任公司 |
環狀化合物、製備方法及其醫藥用途
|
|
CN119301132A
(zh)
|
2022-06-01 |
2025-01-10 |
豪夫迈·罗氏有限公司 |
用于治疗癌症的卤代吲哚大环化合物
|
|
WO2023240263A1
(en)
*
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
EP4582426A4
(en)
*
|
2022-09-19 |
2025-12-24 |
Adlai Nortye Biopharma Co Ltd |
PAN-KRAS INHIBITOR COMPOUND
|
|
CN117720556A
(zh)
*
|
2022-09-19 |
2024-03-19 |
杭州阿诺生物医药科技有限公司 |
一种pan-KRAS抑制剂化合物及其制备方法和用途
|
|
CN119522225A
(zh)
|
2022-09-29 |
2025-02-25 |
广州嘉越医药科技有限公司 |
大环衍生物及其应用
|
|
CN118373832B
(zh)
*
|
2023-01-20 |
2025-01-28 |
深圳晶蛋生物医药科技有限公司 |
大环类化合物、其药物组合物及其应用
|
|
CR20250329A
(es)
|
2023-02-14 |
2025-09-12 |
Hoffmann La Roche |
Compuestos tricíclicos para el tratamiento del cáncer
|
|
EP4687905A1
(en)
|
2023-03-30 |
2026-02-11 |
Revolution Medicines, Inc. |
Compositions for inducing ras gtp hydrolysis and uses thereof
|
|
CN121263418A
(zh)
|
2023-04-07 |
2026-01-02 |
锐新医药公司 |
大环ras抑制剂
|
|
KR20260005904A
(ko)
|
2023-04-07 |
2026-01-12 |
레볼루션 메디슨즈, 인크. |
매크로사이클릭 ras 억제제
|
|
AU2024252105A1
(en)
|
2023-04-14 |
2025-10-16 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
|
KR20250172857A
(ko)
|
2023-04-14 |
2025-12-09 |
레볼루션 메디슨즈, 인크. |
Ras 억제제의 결정형
|
|
CN116284045A
(zh)
*
|
2023-05-18 |
2023-06-23 |
西南交通大学 |
一种手性吲哚单元取代的四氢异喹啉化合物及其合成方法
|
|
EP4720072A2
(en)
*
|
2023-05-26 |
2026-04-08 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN116570599B
(zh)
*
|
2023-07-04 |
2023-10-20 |
四川大学华西医院 |
Vs6766联合ly3009120的应用及药物组合物
|
|
IL326136A
(en)
|
2023-08-07 |
2026-03-01 |
Revolution Medicines Inc |
RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
|
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025090809A1
(en)
*
|
2023-10-25 |
2025-05-01 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
CN117567483B
(zh)
*
|
2023-11-23 |
2025-10-21 |
济南市中心医院 |
一种通过金催化的不对称环加成反应及动力学拆分合成手性氮杂八元环类化合物的方法
|
|
WO2025162395A1
(zh)
*
|
2024-02-01 |
2025-08-07 |
山东先声生物制药有限公司 |
吲哚衍生物作为ras抑制剂及其应用
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025214350A1
(en)
*
|
2024-04-08 |
2025-10-16 |
Sunrise Oncology (Hong Kong) Limited |
Macrocyclic compounds as ras inhibitors for the treatment of cancer
|
|
WO2025217307A1
(en)
|
2024-04-09 |
2025-10-16 |
Revolution Medicines, Inc. |
Methods for predicting response to a ras(on) inhibitor and combination therapies
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026046393A1
(zh)
*
|
2024-09-02 |
2026-03-05 |
山东先声再明生物制药有限公司 |
吲哚类衍生物的制备及其应用
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|